Advertisement
Canada markets open in 5 hours 58 minutes

  • S&P/TSX

    21,728.55
    +14.01 (+0.06%)
     

  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     

  • DOW

    37,903.29
    +87.37 (+0.23%)
     

  • CAD/USD

    0.7294
    +0.0013 (+0.18%)
     

  • CRUDE OIL

    79.55
    +0.55 (+0.70%)
     

  • Bitcoin CAD

    79,137.33
    -393.38 (-0.49%)
     

  • CMC Crypto 200

    1,265.57
    -5.17 (-0.41%)
     

  • GOLD FUTURES

    2,319.90
    +8.90 (+0.39%)
     

  • RUSSELL 2000

    1,980.23
    +6.32 (+0.32%)
     

  • 10-Yr Bond

    4.5950
    -0.0910 (-1.94%)
     

  • NASDAQ futures

    17,539.75
    +101.50 (+0.58%)
     

  • VOLATILITY

    15.14
    -0.25 (-1.62%)
     

  • FTSE

    8,138.11
    +16.87 (+0.21%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6799
    +0.0006 (+0.09%)
     

Elixinol Wellness First Half 2023 Earnings: AU$0.009 loss per share (vs AU$0.023 loss in 1H 2022)

Simply Wall St
·1 min read

Elixinol Wellness (ASX:EXL) First Half 2023 Results

Key Financial Results

  • Revenue: AU$3.46m (up 7.4% from 1H 2022).

  • Net loss: AU$3.40m (loss narrowed by 52% from 1H 2022).

  • AU$0.009 loss per share (improved from AU$0.023 loss in 1H 2022).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Elixinol Wellness Earnings Insights

Looking ahead, revenue is forecast to grow 39% p.a. on average during the next 2 years, compared to a 8.3% growth forecast for the Personal Products industry in Oceania.

Performance of the market in Australia.

The company's shares are down 18% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 6 warning signs for Elixinol Wellness (4 shouldn't be ignored!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.